EUCTR2020-005576-35-HU进行中（未招募）1 期
A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria at the Screening (Visit 1) and/or Vaccination (Visit 2) visits to be eligible for participation in this study; no protocol waivers are allowed. All Investigator assessment-based judgements must be carefully and fully documented in the source documents:
- •1. Subjects must have read, understood, and signed the informed consent form (ICF) prior to participating in the study; subjects must also complete study-related procedures and the subjects must communicate with the study staff at visits and by phone during the study;
- •2. At the Screening visit (Visit 1), male and female subjects must be:
- •Study Populations #1: 18 to 64 (has not yet had his/her 65th birthday) years of age, inclusive;
- •Study Population #2: 65 years of age or older;
- •Study Population #3: 18 years of age or older;
- •3. At Screening (Visit 1) and Vaccination (Visit 2), study populations #1 and #2 must have a body mass index (BMI) of = 18.5 and < 30 kg/m2 for the Phase 2 portion of the study and a BMI of = 18.5 and < 35 kg/m2 for the Phase 3 portion of the study;
- •4. Subjects are considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study;
- •5. Study Populations #1: Subjects must be in good general health prior to study participation, with no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments, as determined by medical history, physical examination, and vital signs. Investigator discretion will be permitted with this inclusion criterion;
- •6. Study Populations #1 and #3: Female subjects of childbearing potential must have a negative serum pregnancy test result at Screening (Visit 1 for the Phase 2 portion) and/or a negative urine pregnancy test result at Vaccination (Visit 2 for the Phase 2 portion; Visit 1 for the Phase 3 portion):
- •Non-childbearing females are defined as:
- •Surgically-sterile (defined as bilateral tubal ligation, hysterectomy or bilateral oophorectomy performed more than one month prior to the first study vaccination); or
- •Post-menopausal (absence of menses for 12 consecutive months and age consistent with natural cessation of ovulation);
- •7. Study Populations #1 and #3: Female subjects of childbearing potential must use an effective method of contraception for one month prior to vaccination (Visit 2) and agree to continue employing highly effective birth control measures for at least one month after the last study vaccination (or in the case of early termination, she must not plan to become pregnant for at least one month after her last study vaccination).
- •The following relationship or methods of contraception are considered to be highly effective:
- •Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal;
- •Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable;
- •Intra-uterine device with or without hormonal release;
- •Credible self-reported history of heterosexual vaginal intercourse abstinence prior to and for at least one month after the last study vaccination. Abstinent subjects who are ovulating should be asked what method(s) they would use should their circumstances change, and subjects without a well-defined plan should be excluded;
- •Female partner;
- •All regions except the US: Vasectomised partner, provided that
排除标准
- •Subjects who meet any of the following criteria at the Screening (Visit 1) and/or Vaccination (Visit 2) visits will not be eligible for participation in this study; no protocol waivers are allowed.
- •All Investigator assessment-based judgements must be thoroughly documented in the source documents:
- •1. Study Populations #1 and #2: According to the Investigator’s opinion, significant acute or chronic, uncontrolled medical or neuropsychiatric illness. Acute disease is defined as presence of any moderate or severe acute illness with or without a fever within 48 hours prior to the Screening (Visit 1) and/or Vaccination visit (Visit 2).
- •‘Uncontrolled’ is defined as:
- •Requiring a new medical or surgical treatment during the three months prior to study vaccine administration;
- •Requiring any significant change in a chronic medication (i.e. drug, dose, frequency) during the three months prior to study vaccine administration due to uncontrolled symptoms or drug toxicity unless the innocuous nature of the medication change meets the criteria outlined in inclusion criterion no. 5(Study Population #1) or no. 8 (Study Population #2) and is appropriately justified and documented by the Investigator.
- •Investigator discretion is permitted with this exclusion criterion and must be carefully and fully documented in the source documents;
- •2. Study Populations #1 and #2: Any chronic medical condition associated with elevated risk of severe outcomes of COVID-19, including obesity, diabetes (type I/II), significant cardiovascular or respiratory disease including asthma, chronic renal failure, disorders of bleeding/coagulation, chronic inflammatory or autoimmune conditions, immunosuppressive conditions (including HIV), and hypertension;
- •3. Study Populations #1 and #2: Any confirmed or suspected current immunosuppressive condition or immunodeficiency, including cancer, human immunodeficiency virus (HIV), hepatitis B or C infection (subjects with a history of cured hepatitis B or C infection without any signs of immunodeficiency at present time are allowed). Investigator discretion is permitted with this exclusion criterion;
- •4. Study Populations #1 and #2: Current autoimmune disease (such as rheumatoid arthritis, systemic lupus erythematosus,
- •multiple sclerosis or narcolepsy). Investigator discretion is permitted with this exclusion criterion, and subjects may be eligible to participate with appropriate written justification in the source document(i.e. subjects with a history of autoimmune disease who are diseasefree without treatment for three years or more, or on stable thyroid replacement therapy, mild psoriasis [i.e. a small number of minor plaques requiring no systemic treatment], etc.);
- •5. Study Populations #1 and #2: Administration of any medication or treatment that may alter the vaccine immune responses, such as:
- •Systemic glucocorticoids at a dose exceeding 10 mg of prednisone (or equivalent) per day for more than seven consecutive days or for 10 or more days in total, within one month prior to the Vaccination visit (Visit 2). Inhaled, nasal, ophthalmic, dermatological, and other topical glucocorticoids are permitted;
- •Cytotoxic, antineoplastic, or immunosuppressant drugs - within 36 months prior to Vaccination (Visit 2);
- •Any immunoglobulin preparations or blood products, blood transfusion – within 6 months prior to Vaccination (Visit 2);
- •6. Study Population #3: Acute disease defined as presence of any moderate or severe acute illness with or without
研究者
相似试验
进行中（未招募）
1 期
A Study to Assess Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsEbolaMedDRA version: 20.0 Level: PT Classification code 10014071 Term: Ebola disease System Organ Class: 10021881 - Infections and infestationsEUCTR2015-000596-27-GBJanssen Vaccines & Prevention BV421
终止
1 期
A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy AdultsSARS-CoV-2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620001308987Accelagen Pty Ltd35
已完成
2 期
Safety, Tolerability and Immunogenicity Study of 2-Dose Heterologous Regimens for Ebola vaccines Ad26.ZEBOV/MVA-BN-FiloEbolaEbola VaccinePACTR201608001734218Janssen Vaccines & Prevention B.V575
进行中（未招募）
1 期
A Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of AgeEUCTR2017-001239-38-DEMedicago R&D Inc.10,000
进行中（未招募）
1 期
A Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of AgeSeasonal influenzaMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001239-38-FIMedicago R&D Inc.10,000